Ercanetide
Ercanetide (NNZ 2591) is a synthetic analogue of a small peptide of cyclic glycine proline (cGP) . Ercanetide shows orally active and cross the blood-brain barrier. Ercanetide shows neuroprotective after ischemic brain injury. NNZ 2591 improves motor function in a rat model of Parkinson's disease. Ercanetide has the potential for the research of ischemic brain injury and angelman syndrome[1][2][3].
Product Specifications
CAS Number
847952-38-9
Product Name Alternative
NNZ-2591
UNSPSC
12352209
Target
Biochemical Assay Reagents
Type
Peptides
Related Pathways
Others
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/nnz-2591.html
Purity
99.98
Solubility
DMSO : 18.75 mg/mL (ultrasonic)
Smiles
C=CC[C@@]12N(CCC2)C(CNC1=O)=O
Molecular Formula
C10H14N2O2
Molecular Weight
194.23
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Peptides
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
MAP Kinase 1 (Mitogen-activated Protein Kinase 1, MAPK 1, MAPK1, ERT1, Extracellular Signal-regulated Kinase 2, ERK2, ERK-2, ERK, MAP Kinase Isoform p42, Mitogen-activated Protein Kinase 2, MAP Kinase 2, MAPK 2, MAPK2, p41mapk, p42-MAPK, P42MAPK, PRKM1, PRKM2)